Heart rate: From risk marker to risk factor

European Heart Journal, Supplement

Volumn 10, Issue F, 2008, Pages

  Borer, Jeffrey S ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Cardiovascular mortality; Heart rate; Risk factor

Indexed keywords

CHOLESTEROL;

CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; HEART INFARCTION; HEART RATE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STABLE ANGINA PECTORIS;

EID: 68349151514     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sun019     Document Type: Review

References (31)

1. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet 1999;353:89-92.
2. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891-897.
3. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904.
4. Miura K, Daviglus ML, Dyer AR, Liu K, Garside DB, Stamler J, Greenland P. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: The Chicago Heart Association detection project in industry. Arch Intern Med 2001;161:1501-1508.
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
6. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782.
7. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004;292:2217-2225.
8. The SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
9. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-764.
10. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003;362:1527-1535.
11. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003;21:1055-1076.
12. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358.
13. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559.
14. Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, Lepper M, Schoenberger JA, Lindberg HA. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980;112:736-749.
15. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality in the Framingham study. Am Heart J 1987;113:1489-1494.
16. Ducimetière P, Richard JL, Claude JR, Warnet JM. Recherche d'autres facteurs de risque des cardiopathies ischémiques. In: INSERM ed., Les cardiopathies ischémiques: incidence et facteurs de risque L'Etude Prospective Parisienne; 1981. 53-120.
17. Seccareccia F, Pannozzo F, Dima F, Minoprio A, Menditto A, Lo Noce C, Giampaoli S; Malattie Cardiovascolari Atcrosclcrotiche Istituto Superiore di Sanita Project. Heart rate as a predictor of mortality: the MATISS project. Am J Public Health 2001;91:1258-1263.
18. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetière P. Heart rate profile during exercise as a predictor of sudden death. N Engl J Med 2005;352:1951-1958.
19. Jouven X, Empana JP, Buyck JF, Canoui-Poitrine F, Kane A, Mouries C, Ducimetière P. Resting heart rate and its changes over years as a risk factor for mortality in the general population: the Paris Prospective Study I. (Abstract). Eur Heart J 2006;27(Suppl. 1):303.
20. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993;125:1148-1154.
21. Collin P, Fox KM. Pathophysiology of angina. Lancet 1990;1:94-96.
22. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001;104:1477-1482.
23. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005;26:967-974.
24. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J 2005;26:943-945.
25. Hjalmarson A, Gilpin EA, Kjekshus J, Schieman G, Nicod P, Henning H, Ross J Jr. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990;65:547-553.
26. Zuanetti G, Mantini L, Hernández-Bernal F, Barlera S, di Gregorio D, Latini R, Maggioni AP. Relevance of heart rate as a prognostic factor in patients with acute myocardial infarction: insights from the GISSI-2 study. Eur Heart J 1998;19(Suppl. F):F19-F26.
27. Lechat P, Hulot JS, Escolano S, Mallet A, Leizorovicz A, Werhlen-Grandjean M, Pochmalicki G, Dargie H; CIBIS II Investigators. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001;103:1428-1433.
28. Chatterjee K, Cheitlin MD, Karliner J eds. Cardiology: An Illustrated Text/Reference. Vol. 2. Philadelphia, PA: JB Lippincott; 1991.
29. Kjekshus J. Importance of heart rate in determining beta-blocker efficacy in acute and long-term myocardial infarction intervention trials. Am J Cardiol 1986;57 (suppl.):43F-49F.
30. Fox K, Ferrari R, Tendera M, Steg PG, Ford I. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study. Am Heart J 2006;152:860-866.
31. Perski A, Hamsten A, Lindvall K, Theorell T. Heart rate correlates with severity of coronary atherosclerosis in young postinfarction patients. Am Heart J 1988;116:1369-1373.